Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alkermes
Biotech
Alkermes eyes orexin ADHD drug as potential ‘company changer’
Alkermes is vying to be the first to push orexin agonists beyond sleep disorders and into broader patient populations like ADHD and fatigue.
Darren Incorvaia
Sep 21, 2026 7:00am
The GLP-like race to keep us awake and make billions doing it
Aug 31, 2026 11:24am
Sarepta CEO to step down as DM1 hits home—Chutes & Ladders
Feb 27, 2026 8:30am
Midsize biotechs form coalition to fight against MFN policy
Feb 25, 2026 1:05pm
Alkermes races to phase 3 after posting another narcolepsy win
Nov 12, 2025 9:30am
Takeda, Alkermes lift lid on narcolepsy rivals as race heats up
Sep 8, 2025 6:47am
